E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ectopic pregnancy or pregnancy of unknown location. |
|
E.1.1.1 | Medical condition in easily understood language |
A pregnancy that is not inside the womb. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014166 |
E.1.2 | Term | Ectopic pregnancy |
E.1.2 | System Organ Class | 10036585 - Pregnancy, puerperium and perinatal conditions |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We aim to show that combination therapy of gefitinib and methotrexate is more effective in the treatment of unruptured ectopic pregnancies and pregnancies of unknown location than methotrexate alone and therefore decrease the number of women requiring surgery for this condition and increase the success rate of medical treatment as well is increasing the number of women eligible for this medical management. |
|
E.2.2 | Secondary objectives of the trial |
To collect data on the efficacy of this drug combination. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Women aged between 18 and 45 inclusive 2. Women with serum hCG greater than 5 3. Women with either a mass which on ultrasound has the appearance of an ectopic pregnancy or a pregnancy of unknown location 4. No clinical evidence of intra-uterine bleeding 5. No pallor 6. No guarding/rigidity on abdominal examination 7. Stable blood pressure and heart rate 8. Normal haemaglobin on full blood examination at day 1. |
|
E.4 | Principal exclusion criteria |
1. History of significant pulmonary disease (eg lung carcinoma including mesothelioma, chronic obstructive airways disease, emphysema, pneumonitis, silicosis, pulmonary fibrosis, severe/brittle asthma, ILD) 2. Abnormal liver indices 3. Abnormal renal indices 4. Abnormal haematological indices 5. Significant pre-existing dermatological condition (eg psoriasis, excema) 5. Significant pre-existing gastrointestinal illness (eg inflammatory bowel disease, bowel carcinoma) 6. Japanese ethnicity. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Tracking successful resolution of the ectopic pregnancy: this will be done using the existing protocols available to track resolution of ectopic pregnancies after medical management of single agent MTX. Serum hCG will be measured at day 1, 4 and 7. The medical treatment will be deemed to be working if serum hCG drops by at least 15% from day 4 to 7, and continues to drop with weekly measurements. Cure will be evidenced by the fact that hCG levels drop below 5 iu/l (lower limit of the assay). In addition, we will be in contact with the patient regularly and on a daily basis for the first week. We will ask the patients to attend for examination if they describe symptoms of possible rupture of the ectopic pregnancy (eg increasingly severe abdominal pain, dizziness). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
We plan to see patients on day of treatment - Day 1 - then Day 4 and 7 when they attend for scheduled appointments at the Pregnancy Support Centre. We will telephone them on days 2,3,5,6 to ask about any adverse events. We will then follow them to resolution of their ectopic when their serum hCG is below 5 iu/l. This time cannot be defined. We will then contact them at 3, 6 , 12 and 24 months to gather information about their mentrual and pregnancy history. |
|
E.5.2 | Secondary end point(s) |
Incidence of side effects: we will document side effects by way of history, examination (if indicated) and investigation (day 4 and 7 renal function tests/liver function tests/full blood count. We will especially note the incidence of side effects specific to gefitinib (rash and lung symptoms indicating possible ILD) and MTX (nausea and vomiting, abdominal pain, neutropenia, liver toxicity).
Tolerablility: we will note whether the regimen is well tolerated by way of history and examination (if indicated). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end with the last participant's telephone call up to 24 months after cure. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |